The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
Open accessAbstract
PURPOSE: To determine the safety, humoral immune response replication, and activity of multiple intratumoral injections of ONYX-015 (replication selective adenovirus) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: This phase II trial enrolled patients with SCCHN who had recurrence/relapse after prior conventional treatment. Patients received ONYX-015 at a dose of 2 × 10 11 particles via intratumoral injection for either 5 consecutive days (standard) or twice daily for 2 consecutive weeks (hyperfractionated) during a 21-day cycle. Patients were monitored for tumor response, toxicity, and antibody formation. RESULTS: Forty patients (30 standard and 10 hyperfractionated) received 533 injections of ONYX-015. Standard treatment resulted in 14% partial to complete regression, 41% stable disease, and 45% progressive disease rates. Hyperfractionated treatment resulted in 10% complete response, 62% stable disease, and 29% progressive disease rates. Treatment-related toxicity included mild to moderate fever (67% overall) and injection site pain (47% on the standard regimen, 80% on the hyperfractionated regimen). Detectable circulating ONYX-015 genome suggestive of intratumoral replication was identified in 41% of tested patients on days 5 and 6 of cycle 1; 9% of patients had evidence of viral replication 10 days after injection during cycle 1, and no patients had evidence of replication ≥ 22 days after injection. CONCLUSION: ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refractory SCCHN. ONYX-015 viremia is transient. Evidence of modest antitumoral activity is suggested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., & Hong, W. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280306 · Cited by 2,211
Self-citationAn Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Self-citationHeise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Self-citationForastiere, A. A., Metch, B., Schuller, D. E., Ensley, J. F., Hutchins, L. F., Triozzi, P., Kish, J. A., McClure, S., VonFeldt, E., & Williamson, S. K. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1245 · Cited by 752
An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain
La Salle, G. L. G., Robert, J. J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L. D., Perricaudet, M., & Mallet, J. (1993) · Science · doi:10.1126/science.8382374 · Cited by 738
Jacobs, C., Lyman, G., Velez-García, E., Sridhar, K. S., Knight, W., Hochster, H., Goodnough, L. T., Mortimer, J. E., Einhorn, L. H., & Schacter, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.257 · Cited by 628
Marsh, M., & Helenius, A. (1989) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60583-7 · Cited by 602
Adenoviruses in the immunocompromised host
Hierholzer, J. C. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.3.262 · Cited by 587
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
Self-citationBarker, D., & Berk, A. J. (1987) · Virology · doi:10.1016/0042-6822(87)90441-7 · Cited by 385
Cited by
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Patients with head and neck cancer who were treated by direct injection of such viruses into their tumor masses underwent limited clinical responses (Nemunaitis et al., 2001), and more encouraging results of a phase II trial in combination with 5-fluorouracil and cysplatin have been reported (Khuri et al.”
BackgroundDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi, S., & Myers, J. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700104 · Cited by 516
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Nano-oncology: drug delivery, imaging, and sensing
Portney, N. G., & Ozkan, M. (2006) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-005-0247-7 · Cited by 456
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450
Self-citationChiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Self-citationMcKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2242 · Cited by 397
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Cancer gene therapy using a survivin mutant adenovirus
Mesri, M., Wall, N. R., Li, J., Kim, R. W., & Altieri, D. C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12983 · Cited by 337
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Oncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
Jin, S., & Ye, K. (2007) · Biotechnology Progress · doi:10.1021/bp060348j · Cited by 283
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Gene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Advances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., Kishimoto, H., Endo, Y., Urata, Y., Tanaka, N., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.026 · Cited by 88
Metadata
- Authors
- Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S., & Kirn, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-15
- Volume
- 19
- Issue
- 2
- Pages
- 289-298
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1961949089
- Cited by
- 471
- References
- 31
- FWCI
- 22.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.